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A40yearoldmanwasadmittedwitha2weekshistoryofheadache,blurredvisionandbilateralopticneuritis.Duringthe6months
period prior to admission he had treated with inﬂiximab infusions for prsoriasis arthritis. He had 0.2 vision in right eye and 0.5
in left Fundoscopy showed moderate disc swelling more on the right than on the left side and right-sided splinter heamorrhages
at the disc margin. The intracranial pressure was normal. He was treated with oral methylprednisolone, 100mg daily for 1 week.
His vision improved gradually and when seen 10 weeks later his visual acuity was 1.0 in both eyes and he had normal visual ﬁelds.
Optic neuritis is a rare but well recognized serious adverse eﬀect of treatments with tumor necrosis factor (TNF) antagonists. This
case report illustrates a rare but typical side eﬀect of a TNF alpha inhibitors used for treating a number of inﬂammatory diseases.
These reactions usually appear during ﬁrst year of treatments and never after the ﬁrst one or two infusions. Both genders and all
ages are aﬀected. In some patients the visual defects are irreversible.
1.Introduction
Headache and bilateral visual impairment in young adults
without obvious MRI abnormalities may represent a diag-
nostic challenge for several medical specialities. Optic neu-
ritis is a rare but well-recognized serious adverse eﬀect of
treatmentswithtumornecrosis factor(TNF) antagonists[1–
3]. This case report illustrates a rare but typical side eﬀect
of a TNF alpha inhibitors used for treating a number of
inﬂammatory diseases.
2.CaseReport
A 40-year-old man was admitted to our outpatient clinic
at the Department of Neurology with a 2-week history
of headache, blurred vision, and bilateral optic neuritis.
He had been of good health except for psoriasis mainly
of the plaquelike type and psoriasis-associated arthritis.
His psoriasis had been treated with topical agents and
was well controlled. The psoriatic spondylitis responded
less well to anti-inﬂammatory therapy. 6 months before
admissionhehadalsobeentreatedwithinﬂiximabinfusions.
Inﬂiximab infusions reduced his arthritis considerably with
less pain and improved functional level. The ﬁfth infusion of
treatment had been given 37 days prior to admission. He was
not on any other medication.
A few days before admission he had noticed headache,
narrowing of his visual ﬁelds, and blurred vision. On
admission to hospital he had 0.2 vision in right eye and 0.5
in left eye with abnormal visual ﬁelds ad modum Donders.
Fundoscopy showed moderate disc swelling more on the
right than on the left side. He had right-sided splinter
heamorrhages at the disc margin. Fluorescein angiography
showed vascular leakage bilaterally, more on the right optic
nerve head than on the left.
A lumbar puncture was performed and the intracranial
pressure was 20cm H2O which is within the normal
range. There was normal CSF cell count and no signs
of intrathecal immunoglobulin productions. A brain MRI
showed hyperdense signals in both optic nerves, more on
the right than on the left side. There was no hyperdense
lesions or demyelination in the CNS. He was treated with
oralmethylprednisolone,100mgperdayfor1weekandthen
tapered oﬀ. His vision improved gradually, and when seen 10
weeks later his visual acuity was 1.0 in both eyes and he had
normal visual ﬁelds.2 Case Reports in Ophthalmological Medicine
Comments. There are several TNF antagonists on the market
and optic neuritis has been reported after treatments with
adalibmumab, inﬂiximab, and etanercept [4]. Although
there might be TNF antagonists available so far not being
connected to this type of adverse eﬀects, our patient declined
any further treatment. This was probably a very wise
decision. Optic neuritis is probably related to this type of
drugs and switching from one TNF antagonists to another
could probably induce the same type of reaction.
Our patient recovered completely within 6-7 weeks
after onset of symptoms and about 2 months after last
TNF antagonist infusion. In most patients vision seems to
improvebutnotallpatientsrecovercompletely.Inaminority
of cases, no improvements have been reported [1]. In nearly
all reports, IV steroids or oral steroids have been given
[4]. Typically, these reactions appear during ﬁrst year of
treatments and never after the ﬁrst one or two infusions.
Both genders and all ages are aﬀected.
TNF antagonist have been used in several inﬂammatory
diseases,andopticneuritishasbeenreportedinpatientswith
rheumatoid arthritis, psoriatic arthritis, inﬂammatory bowel
diseases, and bilateral anterior uveitis [4–6].
In most cases with TNF-antagonist-induced optic neu-
ritis brain, MRI shows enhancements of the optic nerves
but rarely demyelinating lesions in the CNS. There is no
known correlation between TNF antagonist treatment and
multiple sclerosis, MS. There might be a higher rate of
demyelination among patients with inﬂammatory diseases
compared to controls. This might only reﬂect the underlying
predisposition associated to their autoimmune disease. Most
TNF-antagonist-induced optic neuritis cases do not have
CSF bands and patients with MS tolerate TNF antagonists
[7].
The strong association between TNF antagonists and
optic neuritis is probably than much more common that
reported in the literature. It is, however, a severe complica-
tion and the clinical picture should be recognized by those
who are treating these patients.
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